IVIM Health vs CoreAgeRx: Pricing, Protocols, and Reviews

IVIM Health vs CoreAgeRx: quick verdict — IVIM Health stands out for dual 4.9-star third-party ratings and a clinician-guided GLP-1 ID protocol with a GIFT75 free month offer; CoreAgeRx emphasizes predictable flat monthly pricing with no membership fee. This comparison uses only the supplied provider facts and qualifiers.

Key differences at a glance: pricing, protocol, and reviews

The most distinctive differences between IVIM Health and CoreAgeRx are pricing structure and promotions, third-party review ratings, and approach to dosing and membership. Both offer clinician-reviewed telehealth treatment and refer to compounded medications where applicable; regulatory and availability qualifiers apply as supplied.

Pricing and membership model

IVIM Health documents a promotional path that can reduce initial cost: a no-obligation free consultation valued at $75 and a free month membership using code GIFT75. IVIM lists compounded semaglutide at $75/mo and compounded tirzepatide at $133/mo plus a $74.99/mo program fee in captured landing-page text, and elsewhere notes a $99 first month with $174/month ongoing rate. CoreAgeRx markets flat monthly pricing with no membership fee: semaglutide listed at $79/month and tirzepatide at $129/month, described as the same price every month with no price hike.

Early verdict recap

If you prioritize third-party ratings and a structured protocol, IVIM Health is highlighted by the supplied evidence; if you prioritize predictable flat per-month cost and no membership, CoreAgeRx is emphasized in its landing details.

Distinctive comparison areas

1. Third-party reviews and trust signals

IVIM Health is repeatedly reported to have dual 4.9-star ratings on Google and Trustpilot, which the source frames as a rare dual third-party verification. CoreAgeRx captured landing content did not show comparable verified third-party ratings in the supplied evidence.

2. Pricing transparency and predictability

CoreAgeRx promotes flat pricing every month with no membership fee and warns other programs can increase bills over time. IVIM presents promotional entry options including a free consultation and code GIFT75, but the ongoing rate and program fees are noted in the supplied material and may result in higher ongoing costs than CoreAgeRx’s flat pricing depending on the plan.

3. Program approach and clinical claims

IVIM advertises a proprietary GLP-1 ID protocol that the source says may accelerate outcomes, describing a claim that patients following the IVIM Protocol lost an average of 46% more weight over 68 weeks compared to another published trial, with the explicit qualifier that this was not a head-to-head study and that the 40% faster claim is proprietary. CoreAgeRx emphasizes short online visits and consistency of treatment pricing; the supplied CoreAgeRx evidence does not include clinical outcome claims comparable to IVIM’s protocol claim.

4. Medication format and regulatory notes

Both providers reference compounded formulations in the captured material. IVIM repeatedly notes that its compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality, and that compounded medications are prescribed only after consultation. CoreAgeRx’s captured text also includes the qualifier that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.

How treatment initiation differs

IVIM’s captured materials highlight a structured onboarding including a clinician evaluation and weekly dose adjustments under its GLP-1 ID approach, plus program fees mentioned. CoreAgeRx emphasizes a 3-minute online visit and the same monthly price without a membership fee; the supplied evidence notes users should confirm eligibility, medication, total cost, renewal terms and state availability before enrolling.

Safety and availability notes

Both sources include regulatory qualifiers. IVIM explicitly states compounded drugs are not FDA-approved and have not undergone FDA review for safety, efficacy, or quality and that products are not available in all states. CoreAgeRx notes medication-specific approval status must be confirmed and that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

Conclusion: Choose based on reviews, pricing, or predictability

IVIM Health vs CoreAgeRx comes down to what you prioritize: IVIM Health is presented in the supplied evidence as the choice for patients who value dual 4.9-star third-party ratings and a clinician-guided proprietary protocol with promotional entry options. CoreAgeRx is presented as the choice for people who prioritize the same price every month and no membership fee. Both require clinician review and include regulatory qualifiers on compounded medications.

Choose IVIM Health if you want a clinician-guided GLP-1 ID protocol with dual 4.9-star ratings and a free month offer. Choose CoreAgeRx if you need flat monthly pricing with no membership fee and predictable monthly cost.